Table 4.
Incidence rate of PDD according to quartiles of glucose variability (other measures).
| Glucose variability | Patients (N) |
Event (n) |
Person-years (PYs) |
Incidence rate (per 1,000 PYs) | Model 1* | Model 2** |
|---|---|---|---|---|---|---|
| VIM | ||||||
| quartile 1 | 2,316 | 371 | 20,418 | 18 | 1 (ref) | 1 (ref) |
| quartile 2 | 2,316 | 410 | 20,196 | 20 | 1.21 (0.96–1.52) | 1.21 (0.96–1.52) |
| quartile 3 | 2,316 | 446 | 19,305 | 23 | 1.24 (0.98–1.55) | 1.23 (0.98–1.55) |
| quartile 4 | 2,316 | 530 | 17,864 | 30 | 1.48 (1.19–1.85) | 1.49 (1.18–1.87) |
| ARV | ||||||
| quartile 1 | 2,195 | 342 | 19,301 | 18 | 1 (ref) | 1 (ref) |
| quartile 2 | 2,423 | 429 | 21,098 | 20 | 1.12 (0.89–1.42) | 1.11 (0.88–1.41) |
| quartile 3 | 2,309 | 460 | 19,414 | 24 | 1.29 (1.02–1.62) | 1.28 (1.02–1.61) |
| quartile 4 | 2,337 | 526 | 17,971 | 29 | 1.40 (1.11–1.76) | 1.39 (1.10–1.77) |
*Model 1 was adjusted for age, sex, presence of hypertension, diabetes and hyperlipidemia, heavy alcohol consumption, smoking, and regular exercise in the Fine and Gray competing regression model, including glucose variability as a separate predictor and death as a competing risk.
**Model 2 was adjusted for all covariates in model 1 plus systolic BP, diastolic BP, fasting glucose, total cholesterol, and BMI at index health examination in the Fine and Gray competing regression model.
PDD, Parkinson’s disease dementia; PY, person-year; VIM, variability independent of mean; ARV, average real variability.